A Safe Start To Bipartisan Pricing Action
This article was originally published in RPM Report
The first “official” Congressional response to the drug pricing debate is a planned hearing in the Senate Special Committee on Aging. While the biopharma industry would prefer other topics of discussion, the forum and focus are about as good as they could be for innovator companies.
You may also be interested in...
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
Commissioner Hahn’s role in the EUA for convalescent plasma has understandably roiled the world of FDA watchers. But what about the EUA that FDA still has not granted as a treatment for COVID-19?